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Since the first report of a mutation in the tyrosinase gene that 
causes tyrosinase-negative oculocutaneous albinism (OCA), 
more than 25 alleles with a different mutation in patients 
with three types of OCA, i.e., tyrosinase-negative OCA 
(type IA), yellow-mutant OCA (type m), and temperature 
sensitive OCA (type ITS), have been found in several labora­
tories. The mutated alleles are presendy classified into three 
types. The first and the second group of alleles, termed r and 
O culocutaneous albinism (OCA), characterized by a decrease in melanin pigment in the skin, hair, and eyes, comprises a heterogeneous group of inherit­able disorders. Witkop et al [1) described 10 types of OCA of which type IA (tyrosinase-negative albi­
nos) and type IB (yellow mutant albinos) are due to no or low 
activity of tyrosinase. Tyrosinase, which catalyzes the conversion of 
tyrosine to dihydroxyphenylalanine (dopa), is a key enzyme for 
melanin biosynthesis in pigment cells [2). Recent progress in molec­
ular biology has made it possible to isolate tyrosinase genes from 
normal subjects and albino patients and to determine their nucleo­
tide sequences. By comparing patients' sequences with those of 
normal subjects, it has become possible to clarify many mutations 
causing various types of albinism. 
In 1986, Shibahara et al [3) reported a mouse tyrosinase cDNA 
clone candidate, pMT4, and in 1987 Kwonetal[4) and Yamamoto 
et al [5) cloned tyrosinase cDNA, Pmel34, and Tyrs-33 from the 
human and the mouse, respectively. As these cDNA clones are 
similar to, but definitely different from, each other in their nucleo­
tide sequences, there was some confusion and disagreement 
whether there might be several isozymes of tyrosinase. In 1988, 
Ruppert et al [6) and Muller et at [7) determined that pMT4 encodes a 
protein at the b-Iocus, termed "tyrosinase-related protein" by Jack­
son [8), and that pmel34 encodes human tyrosinase, whereas Tyrs-
33 is one of three cDNAs resulting from alternative splicing of the 
primary transcript of a single tyrosinase. Since then, many re­
searchers have been attempting to clarify the pathologic mutations 
that cause tyrosinase-related albinism. 
In this review, the pathologic mutations found in tyrosinase 
genes of OCA patients are described and the relationship between 
genotypes and phenotypes of various OCA explained. 
CLASSIFICATION OF OCA 
Human OCA is classified into two major types, tyrosinase related 
(type I) and tyrosinase positive (type II) OCA. Type I results from 
abnormalities of the tyrosinase gene. On the other hand, the tyro-
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y, produce tyrosinases with no enzyme activity and with very 
low activity, respectively. The third, termed ts, produces tem­
perature-sensitive tyrosinase with very low activity at 35°C, 
but with no activity at temperatures greater than 35°C. 
Various combinations of these alleles result in tyrosinase-ne­
gative (r/r), yellow mutant (y/y, y/r, y/ts), or tempera­
ture-sensitive (ts/r, ts/ts) OCA.JlnvestDermatoI100:186S-
1905, 1993 
sinase gene is normal in type II, which, therefore, results from a 
defect in unknown gene(s). Both types of OCA have autosomal 
recessive inheritance [I). 
At present, type I OCA is subdivided into three types. The first is 
tyrosinase-negative OCA (type IA), which is completely lacking in 
tyrosinase activity and therefore shows no melanin formation dur­
ing the life of the patient, i.e., its phenotype is white hair and skin, 
and red eyes throughout life [1). The second type is yellow-mutant 
OCA (type IB), which shows little pigment at birth but rapidly 
develops yellow hair pigment in the first few years of life and then 
continues with a slow accumulation of pigment in the hair, eyes, 
and skin over time. The hair bulbs of a patient with yellow OCA 
show the presence of tyrosinase but with very low activity [I). The 
third type is a newly described one, namely, temperature-sensitive 
OCA (type ITS) [9J. A patient with type ITS has white skin, blue 
irises, and white axillary and scalp hair, but has lightly pigmented 
arm hair, and dark brown leg hair. Melanin production is dependent 
on the skin temperature in each area of the patient's body [9); the 
warm areas have no pigment but the cooler areas do have pigment. 
All three subtypes result from different mutations of the tyrosinase 
gene, which have been clarified in these three years. 
Tyrosinase-positive OCA (type II) is thought to result from 
various gene defects, because its phenotypes are various. The lack of 
molecular characterization prevents the classification of type II 
OCA and the clarification of their pathogeneses. Therefore, only 
type I OCA will be addressed in this review. 
TYROSINASE cDNA AND ITS DEDUCED AMINO 
ACID SEQUENCE 
Human tyrosinase cDNA, pmel34, was cloned and its nucleotide 
sequence was reported by Kwon et at in 1987 [4). Recently, they 
have corrected their initially reported sequence of pmel34 [10). We 
have also isolated human tyrosinase cDNA, pHTI'I, using a syn­
thetic oligonucleotide complementary to a segment of pmel34 and 
determined the sequence of tyrosinase cDNA for comparison with 
.sequences of albino patients to find new mutations of the tyrosinase 
'gene [11). 
The amino acid sequence deduced from human tyrosinase cDNA 
is shown in Fig 1. It is composed of 529 amino acids and the first 18 
amino acid residues at the N-terminal region constitute a signal 
peptide [11,12). Secretory and membrane-associated proteins usu­
ally contain a signal peptide that enables such proteins to cross a 
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· . . . . . 
1 MLLAVLYCLLWSI'QTSAGIII'PRACVSSKNLMEKECCPPWSGDRSPCGQLSGRGSCQNILL 
(-18) (1) 
· . . . . . 
61 SNAPLGPQI'PI'TGVDDRESWPSVI'YNRTCQCSGNFMGI'NCGNCKFGFWGPNCTERRLLVR 
(43) 
· . . . . . 
121 RNIFDLSAPEKDKFFAYLTLAKITTISSDYVIPIGTYGQMKNGSTPMFNDINIYDLl'VIVMH 
(103) 
181 YYVSMDALLGGSEIWRDIDFAHEAPAFLPIYITRLFLLRWEClEIQKLTGDENl'TIPYlVDWRD 
(163) 
· . . . . . 
241 AEKCDICTDEYMGGQIIPTNPNLLSPASFFSSWQIVCSRLEEYNSIIQSLCNGTPEGPLRRN 
(223) 
301 PGNHDKSihpRI.PSSADVEFCLS L TQYESGSMDKAAN FSF L!NTLEGF ASPL TG IADIISQS 
(283) 
361 SMLLNIlLILIY�1NGTMSQVQGSANDPIFLLLLiLAFVDSIFEQWLHRHRPLQEVYrEANArIG;! 
(343) . 
· . . . . . 
421 NRESYMVrFIPLYRNGDl'l'ISSKDLGYDYSYLQDSDPDSFQDYIKSYLEQASRIWSWLLG 
(403) ••••••• 
481 AIIMVGIIVLTALLAGLVSLLCRLLKRKQLPEEKQPLLMEKEDYITSLYQSIlL 529 
(463)··················· (511) 
Figure 1. Amino acid sequence of human tyrosinase deduced from its 
eDNA. The deduced amino acids are shown by single-letter codes and are 
numbered starting from the amino-terminal residue of the transcribed 
tyrosinase [11]. The numbers in parentheses are those starting from the 
amino-terminal residue of the mature tyrosinase and the preceding resi­
due of a signal peptide is indicated by a negative number. The additional 
amino acids (Y at 192, T at 308, Q at 402, and P at 495) are reported to be 
non-pathologic polymorphisms. Putative copper-binding regions are un­
derlined. Asterisks, transmembrane segments. 
membrane, and the peptide is removed during the process [13,14]. 
The melanosome-bound form of mature tyrosinase, which removes 
the 18 amino acids of the signal peptide, is thus composed of 511 
amino acids, having a molecular weight of 58,000, with histidine at 
the N-terminal [11], as confirmed by the analysis of its amino acid 
sequence by Wittbjer et al [15]' 
Recently Giebel et al [16], and Bouchard et al [17] have reported 
that several common non-pathologic polymorphisms in the tyro­
sinase gene are found in Caucasians, and these cause an alteration of 
the amino acids at 192 and 402 as shown in Fig 1. Chintamaneni et al 
[10] have also described two other polymorphisms that alter the 
amino acids at 308 and 495 (Fig 1). 
When we previously reported the nucleotide sequence of tyro­
sinase cDNA, we numbered the codons starting from the codon of 
histidine, the N-terminal of mature tyrosinase, because the se-
9uence of the signal peptides was not fully determined at that time 
[11]. However, many researchers have recently adopted a system of 
numbering from the N-terminal of the signal peptides [18], thus 
making it somewhat difficult to compare the sites of point muta­
tions we found in the tyrosinase gene of albino patients with the 
ones they found. We would therefore like to renumber the codons 
of tyrosinase cDNA in accordance with the system now more com­
monly employed, starting from the N-terminal of the signal pep­
tides at which 18 amino acids have already been confirmed, as 
shown in Fig 1. 
Tyrosinase is known to have two Cu++ [19] and we tentatively 
assign two regions, amino acid residues 172-238 and 361-403, as 
the copper-binding sites [11]. At each copper-binding site, three or 
four histidine residues are present, and some of them conceivably 
serve as the ligands of the two coppers of tyrosinase. Mature tyrosin­
ase contains 16 cysteine residues, which are probably involved in the 
construction of the tertiary structure of the protein. There are six 
potential N-glycosylation sites, which are asparagine residues. Be­
cause human tyrosinase contains four asparagine-linked sugar 
chains per molecule [20], some of these residues are functional N­
glycosylation sites. This glycosylation is linked with the transfer of 
tyrosinase from the rough endoplasmic reticulum to the melano­
some via the Golgi complex [21]. Human tyrosinase also contains a 
putative transmembrane segment near the carboxyl terminus (resi­
dues 474-499) [11]. 
Mouse tyrosinase cDNA has been isolated by several research 
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Figure 2. Structure of the human tyrosinase gene. The five boxes (1-5) 
represent the five exons of the tyrosinase gene [11,26]. Numbers under 
the boxes represent the codon number of the first or the last codon of each 
exon.lEiI, putative copper-binding region .• , the transmembrane segment. 
groups [7,22-25]. The amino acid sequence homology between 
mouse tyrosinase and human tyrosinase is about 86% [11]. 
TYROSINASE GENE 
We have cloned and sequenced the genomic DNA segment of the 
protein coding region obtained from the human tyrosinase gene 
[11,26]. The human tyrosinase gene is organized into five exons, as 
shown in Fig 2, and its size is thought to be more than 70 kb [11,27]. 
These findings were confirmed by Giebel et al [16]. Barton et al [28] 
reported that the tyrosinase gene is localized in the long arm of 
chromosome 11 in region 11q14-q21. The human genome con­
tains additional sequences cross-hybridizing to the exon 4 and exon 
5 tyrosinase gene [29], mapped to the short arm of chromosome 11, 
near the centromere (pl1.2-cen) [28]. The additional sequences are 
tyrosinase pseudo genes, which share more than 98% nucleotide 
homology with exon 4 and exon 5 of the human tyrosinase gene 
[16,29,30]. 
The nucleotide sequence of the promoter region located up­
stream from the tyrosinase coding region and its function have been 
partially elucidated [16,31]. 
TYROSINASE GENE MUTATION 
In 1989 we found a pathologic mutation of the tyrosinase gene for 
the first time in a patient with oculocutaneous albinism [26]. Since 
then a number of various mutations have been reported by several 
research groups [10,18,27,32-42] as summarized in Table I. All of 
these mutations are located in the protein coding region, but none in 
the promoter region. They are classified into several kinds of muta­
tions, i.e., a missense mutation, a nonsense mutation, and a frame 
shift mutation. A missense mutation denotes an alteration of one 
nucleotide that causes a codon specific for a given amino acid to 
specify another amino acid. On the other hand, the change to a 
termination codon such as TAA, TAG, and TGA at which the 
protein synthesis on the ribosome stops is known as a nonsense 
mutation. Frame-shift mutations found in the tyrosinase gene as 
shown in Table I are a single-base insertion, or a single/double/four 
base deletion in the coding region that causes the frame shift of 
triplets (codons) and finally introduces a termination codon. Four of 
seven insertion/deletion mutations found in OCA patients reside 
within repetitive base sequences, i.e., CCCC [26], GGGGG [36], 
GTGTG [36], and CTTT [42]. Streisinger et al [43,44] have sug­
gested that the repetitive sequence allows slippage and misalign­
ment of the two DNA strands, with a looping out of one or more 
bases, and subsequent DNA synthesis would then either omit or add 
a nucleotide or nucleotide pair. 
New tyrosinase proteins arising by missense mutations contain 
only single amino acid replacements. However, they are character­
ized by various extents of tyrosinase activity that can be classified 
into four groups (Table II). The first group consists of mutations in 
which tyrosinase activity remains as high as that of the original one; 
this group of alleles belongs to a wild allele termed T+, and can 
therefore be regarded as a polymorphism because it has no patho­
logic significance. Many nonpathologic polymorphisms in the 
human tyrosinase gene have already been reported [16,17]. The 
second group of mutated alleles, the tyrosinase of which completely 
loses its enzyme activity, is tentatively termed t-. In the third 
group, the alleles termed y produce enzymes with very low activity. 
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Table I. Mutations Associated with Tyrosinase-Related DCA 
Number of Amino 
Type of Codon Acid of Mature 
Allele (No.) Tyrosinase Exon 
t- 42 24 1 
C 47 29 1 
t- 55 37 1 
C 77 59 1 
C 81 63 1 
t- 89 71 1 
t- 96 78 1 
t- 176 158 1 
t- 178 160 1 
C 191 173 1 
C 206 188 1 
C 217 199 1 
t- 244 226 1 
y 275 257 2 
C 310 292 2 
C 371 353 3 
t- 373 355 3 
t- 378 360 3 
t- 382 364 3 
t- 383 365 3 
y 406 388 4 
t- 419 401 4 
15 422 404 4 
t- 438 420 4 
C 453 435 4 
t- 490 472 5 
C 501 483 5 
• Term, termination signal. 
In the fourth, the allele termed ts produces enzyme with very low 
activity at 31°C, but decreasing to almost no activity around 37°C. 
Half of the missense mutations found in 16 c alleles localize in 
two copper-binding regions (codon 172 -238 and codon 361-403) 
and a substituted amino acid is assumed to change the steric confor­
mation at the copper-binding site or at the active site of the enzyme, 
which can then completely inhibit its catalytic function. Most of the 
other missense mutations are in exon 1 (Table I) and, at present, no 
one can explain why or how substituted amino acids, eg, leucine 
from proline and glutamine from· arginine, change the tertiary 
structure of the enzyme protein into an inactive form except for the 
case of tyrosine/arginine substitution from cysteine whose side 
group "SH" usually involves the stereochemical structure of pro­
tein. 
There have been several reports of insertion or deletion mutations 
of tyrosinase gene, all of them inducing a nonsense codon that 
produces incomplete tyrosinase protein with no activity (Table I). 
These also can be classified into the second group, r (Table II). 
GENOTYPES AND PHENOTYPES 
DF VARIOUS OCA 
Three types of OCA caused by tyrosinase gene mutations are now 
known, i.e., type IA OCA [1], yellow mutant (type IB) OCA [1,38], 
and temperature-sensitive OCA (type ITS) [9,40J. These three phe­
notypes genetically atise from various combinations of the three 
Table D. Alleles of Tyrosinase and the Enzyme Activity of 
Their Products 
Allele 
T+ 
C 
Y 
15 
Tyrosinase Activity 
in Product 
High 
None 
Very low 
Very low at 35°C 
None at 37°C 
Nucleotide Amino Acid 
Substitution Substitution" References 
GAC�GGC Asp(D) � Gly(G) [41] 
GGC�GAC Gly(G) � Asp(D) [32] 
TGT�TAT Cys(C) � Tyr(Y) [41] 
CGG�CAG Arg(R) � Gln(Q) [27,33] 
ccr�CTI Pro(P) --+ Leu(L) [34] 
TGC�CGC Cys(C) --+ Arg(R) [35] 
ATG�AATG Term 168 [36] 
TIT--+ATT Phe(F) --+ ne(I) [42] 
TGG--+TAG Trp(W) --+ Term [37] 
GGAT�GAT Term 225 [36] 
GCT�ACT Ala(a) --+ Thr(T) [41] 
CGG�CAG Arg(R) --+ Gln(Q) [42] 
TGTGA�TGA Term 244 [36] 
GTC�TIC Val(V) --+ Phe(F) [38] 
CCA�CCCA Term 317 [26] 
AAT�Acr Asn(N) --+ Thr(T) [32] 
ACA�AAA Thr(T) --+ Lys(K) [39] 
CAG�TAG Gln(Q) � Term [42] 
AAC�AAA Asn(N) --+ Lys(K) [36] 
GAT�AAT Asp(D) � Asn(N) [39] 
ccr�CTI Pro(P) --+ Leu(L) [38] 
GGA�AGA Gly(G) --+ Arg(R) [41] 
CGG�CAG Arg(R) � Gln(Q) [40] 
Delete CTTT Term 484 [42] 
CAA�TAA Gln(Q) � Term [42] 
GCC�TGCC Term 509 [10] 
CGT�CCGT Term 509 [38] 
alleles, as shown in Table III. A person with one allele of the wild 
tyrosinase gene (r+) always expresses normal skin pigmentation 
even if the other allele is r, y, or ts. That is, the subject is a carrier 
(heterozygous) of the mutated gene, which means that melanin 
production is fully realized by half the amount of tyrosinase synthe­
sized in a normally pigmented person. 
In a patient with tyrosinase-negative DCA, melanin formation 
never occurs throughout the patient's life [1] because the patient's 
genotype is homozygous r allele [10,18,26,27,32-37,39,41]. 
Yellow mutant albino patients completely lack detectable pig­
ment at birth and are initially indistinguishable from patients with 
tyrosinase-negative OCA. However, patients with yellow mutant 
OCA accumulate some melanin pigment, principally yellow-red 
pheomelanin, during childhood and adulthood [1,38]. The geno­
type of yellow mutant OCA is reported to be y X r; that is, the 
patient has very low tyrosinase activity [38]. The reason melanin 
accumulation develops with the patient's growth is unclear. A pa­
tient with homozygous y allele has also been reported [38], the 
phenotype also being yellow mutant DCA. 
A patient with temperature-sensitive OCA analogous to that of 
the Siamese cat and the Himalayan mouse has been recently re­
ported by King et al [9]. The patient had white hair and skin, and 
blue eyes at birth, and a diagnosis of OCA was made. At puberty, she 
Tablem. Relation between Genotype and DCA Phenotype 
Allele T+ t- Y 15 
T+ Normal Normal Normal Normal 
(T+/T+) (T+/q (T+/y) (T+ /15) 
t- Normal ty-neg ym tern-sen 
(t-/T+) (t-/q (t-/y) (t-/15) 
y Normal ym ym ym 
(y/T+) (y/q (y/y) (y/15)" 
15 Normal tern-sen ym tern-sen 
(15/T+) (15/C) (15/y)" (15/15)" 
• No patient with the indicated genotype has yet been detected. ty-neg, tyrosinase-
negative OCA; ym, yellow mutant OCA; tern-sen, temperature·sensitive OCA. 
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developed progressively darker hair in the cooler areas (extremities), 
but retained white hair in the warmer areas (scalp and axilla) [9]. 
This clinical feature is explained genetically as follows. The pa­
tient's genotype is ts X r; the ts gene produces temperature-sensi­
tive tyrosinase, which has very low activity at 35°C and loses its 
activity above 35 ° C, whereas the r gene produces inactive tyrosin­
ase [35]. A patient with homozygous ts may be also diagnosed as 
having yellow mutant OCA, but a patient with ts X Y would proba­
bly be diagnosed as suffering from yellow mutant OCA. However, 
there have been no reports of such cases to date. 
Patients with tyrosinase-positive OCA have more or less tyrosin­
ase activity in their melanocytes. Therefore, this type of OCA .is 
thought to be due to a defect of factors involving melanogenesis 
other than tyrosinase. There must be heterogeneous causes of tyro­
sinase-positive OCA, because its clinical features are so various: 
some patients already have yellow or blond hair at birth, whereas 
some have white hair throughout their lives. We checked the tyro­
sinase gene of one patient with tyrosinase-positive OCA, but found 
no mutation [45]. However, I believe that a subtype of tyrosinase­
positive OCA exists that is caused by a frame-shift mutation at the 
membrane binding region of tyrosinase, which causes the reading 
frame to shift and the amino acid sequence of the membrane binding 
region to change. Such tyrosinase probably has enough enzyme 
activity but cannot bind with the melanosome membrane, resulting 
in the non-occurrence of physiologic melanogenesis in the patient's 
melanocytes. The region from the transmembrane to the carboxyl 
terminal of tyrosinase is not crucial for the enzyme activity because 
trypsin digestion of the membrane-bound tyrosinase results in a 
soluble tyrosinase with full enzyme activity [15]. 
The molecular bases of OCA caused by tyrosinase gene mutation 
have been rapidly clarified over the past three years as described in 
this review. For the future, the systematic procedure of gene diag­
nosis in various types of tyrosinase-related OCA is expected to be 
well established. 
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